Table 1.
Study parameters.
Table 2.
Incremental costs, health outcomes, and ICERs across five presidential regimes.
Fig 1.
Markov state-transition model with healthy, infected, treated, and dead health states.
Table 3.
Characterizing uncertainty (Single study-based evaluation).
Table 4.
Characterizing uncertainty (Model-based evaluation).
Table 5.
Characterizing heterogeneity.
Fig 2.
Deterministic sensitivity analysis of ICER ranges with base-case reference line (NGN 1000/DALY).
Fig 3.
Cost-effectiveness acceptability curve showing probability of cost-effectiveness across willingness-to-pay thresholds.
Fig 4.
Subgroup ICER comparisons illustrating heterogeneity relative to base-case ICER reference line.